Phase 2
N=13
Acetyl-L-Carnitine in the Treatment of Septic Shock
Septic Shock
Bottom Line
View on ClinicalTrials.gov: NCT00592488 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jun 2011
Primary outcome: Primary: Mean Arterial Blood Pressure — 60; 60 mm Hg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Acetyl-L-Carnitine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University
- Primary completion
- Aug 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Arterial Blood Pressure |
60; 60 | — |
| SECONDARY Vasopressor Dose |
-1.4; -4.8 | — |
| SECONDARY Serum Lactate |
2.1; 2.0 | — |
Summary
This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.
Eligibility Criteria
Inclusion Criteria
- documented or presumed infection
- shock requiring vasopressors
Exclusion Criteria
- dialysis
- hepatic failure
- seizures
Data sourced from ClinicalTrials.gov (NCT00592488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.